Understanding Unmet Needs in the Frontline Ph+ ALL Treatment Landscape

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding Unmet Needs in the Frontline Ph+ ALL Treatment Landscape



ReachMD Healthcare Image

Learn more about the treatment challenges for frontline Ph+ ALL, including lack of approved frontline therapies and other care gaps in the disease landscape.

  • Sponsored by

  • Overview

    For patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), treatment can be challenging due to lack of approved therapies and consensus on how to approach frontline care. To help us better understand this, Dr. Hagop Kantarjian from The University of Texas MD Anderson Cancer Center dives into the treatment of Ph+ ALL.

    TAKEDA® and the TAKEDA logo® are registered trademarks of Takeda Pharmaceutical Company Limited.
    © 2023 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved
    03/23 USO-NON-0529

Schedule4 Jun 2023